Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReNovaCell grafting plus standard care for stable non-segmental vitiligo
NL-OMON46274Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of ReNovaCell in Vitiligo, sponsored by Amsterdam University Medical Center. Started Feb 2017; status: active, not recruiting.
02
Drugs
ReNovaCell
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NL-OMON46274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46274.